BusinessBiothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer ImmunotherapyBy Nasdaq OMXFeb 24, 2017, 7:24 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck CancerBy Nasdaq OMXDec 5, 2016, 2:30 PM UTC
BusinessFluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology ResearchBy Nasdaq OMXNov 10, 2016, 1:30 PM UTC
BusinessFluidigm Announces New Integrated Fluidic Circuits for Single-Cell Genomics on the C1 SystemBy Nasdaq OMXApr 12, 2016, 12:44 PM UTC
